整理 | GLP1减重宝典内容团队 ACR50 是美国风湿病学会用于评估疾病修饰抗风湿药（DMARD）疗效的重要指标，意味着患者在关节肿胀、疼痛和功能方面获得具 有临床意义的改善。 在关键次要终点上，联合治疗同样表现突出。Taltz + Zepbound 组中，33.5% 的患者达成 ACR50，应答率较 Taltz 单药组（20.4%）实 现了 64% 的相对提升，显示出两种机制在 PsA 治疗中的协同效应。 从安全性来看，联合治疗的治疗期间不良事件（TEAE）与两种药物各自已知的安全谱一致，最常见不良反应包括恶心、腹泻、便秘以 及注射部位反应，并未出现新的安全信号。 ▍ 从"免疫抑制"到"代谢 + 炎症"的整合治疗 Taltz 通过抑制 IL-17 炎症通路发挥作用，自 2016 年获批治疗成人斑块型银屑病以来，已扩展至儿童适应证，并成为礼来免疫学板块 的重要产品。仅 2024 年，Taltz 就为礼来贡献了约 32 亿美元收入，预计销售额将在 2029 年前持续增长，并在当年达到约 40 亿美元峰 值。 礼 来 正 在 将 GLP-1 类 药 物 的 边 界 不 断 向 " 减 重 之 外 " 推 开 ...

Core Insights - Eli Lilly and Johnson & Johnson both reported strong third-quarter results, indicating robust performance in their respective healthcare sectors [1] Company Performance - Eli Lilly and Johnson & Johnson demonstrated fundamentally different healthcare business models despite both achieving strong earnings [1]

Core Insights - The GLP-1 market is transitioning from weekly injections to daily oral pills, with Novo Nordisk's Wegovy pill already available and Eli Lilly's expected soon, indicating a significant shift in obesity treatment options [1][7][30] Market Dynamics - The introduction of oral GLP-1 pills is expected to attract new patients, particularly those who prefer pills over injections, potentially expanding the obesity treatment market significantly [4][8] - Goldman Sachs analysts project that oral pills could capture approximately 24% of the global weight-loss drug market by 2030, equating to about $22 billion [7][30] Pricing and Accessibility - Novo Nordisk's Wegovy pill is priced between $149 and $299 per month, making it a more affordable option compared to the cash prices of injections, which have been reduced to around $349 per month [2][13][15] - Patients with insurance may pay as little as $25 per month for the oral drug, although overall insurance coverage for GLP-1s remains uncertain [16][18] Patient Preferences - Many patients may prefer pills due to convenience and lower costs, with some expressing interest in switching from injections to oral medications [5][12][24] - The convenience of oral medications may appeal to those who are needle-averse or do not perceive their condition as severe enough to warrant injections [4][10] Competitive Landscape - Eli Lilly's oral GLP-1 is anticipated to be more convenient due to its absorption characteristics and lack of dietary restrictions compared to Novo Nordisk's pill [25][30] - Other pharmaceutical companies, including Pfizer and AstraZeneca, are also developing oral GLP-1 options, indicating a competitive race in the market [31][33] Efficacy and Treatment Options - Clinical trials suggest that while pills may not provide greater weight loss than injections, they could still be effective for patients seeking modest weight loss [3][21] - The highest dose of Novo Nordisk's Wegovy pill resulted in an average weight loss of 16.6% over 64 weeks, comparable to its injectable form [28]

ipopba / iStock via Getty Images Quick Read FHLC charges just 0.084% in fees but carries 13% concentration in Eli Lilly. The fund gained 17.9% over one year but returned only 154% over ten years versus the S&P 500’s 235%. Enhanced ACA premium tax credits face 87.5% probability of expiring by January 31 2026. Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected. Healthcare investing offers ...

Core Insights - Healthcare investing is characterized by defensive traits during market volatility, but regulatory and political risks can lead to abrupt selloffs [1] - Fidelity MSCI Health Care Index ETF (FHLC) offers a low-cost entry point for investors seeking exposure to the healthcare sector without selecting individual stocks [1] Fund Overview - FHLC tracks the MSCI USA IMI Health Care Index, providing exposure to U.S. healthcare companies across various segments including pharmaceuticals, biotechnology, medical devices, and health insurance [2] - The fund has an expense ratio of 0.084% and includes over 80 holdings, focusing on capital appreciation and modest dividend income [2] Concentration Risk - Eli Lilly constitutes over 13% of FHLC's portfolio, linking its performance closely to GLP-1 obesity drugs, which have seen a 46% increase in stock price over the past year [3] - The top five holdings also include UnitedHealth, Johnson & Johnson, Merck, and AbbVie [3] Performance Analysis - FHLC has shown strong short-term performance, gaining 5.3% in the last month and 17.9% over the past year, outperforming the S&P 500 [4] - However, over five years, FHLC returned 42.6%, significantly lagging behind the S&P 500's 84.5% return, with a widening gap over ten years (154% vs. 235%) [4] Sector Challenges - The underperformance of FHLC reflects broader challenges in the healthcare sector, including drug pricing pressures and slower innovation cycles outside oncology and rare diseases [5] - Recent momentum may indicate potential sector rotation, but investing after outperformance carries inherent risks [5] Policy and Income Considerations - Investors face political and regulatory uncertainties, with an 87.5% probability that enhanced ACA premium tax credits will expire by January 2026, impacting health insurers like UnitedHealth [7] - FHLC's yield of 1.33% is considered modest compared to other market alternatives, with dividend growth of approximately 4.6% annually over five years, barely keeping pace with inflation [8] Suitability for Investors - Growth-focused investors seeking maximum capital appreciation may find FHLC unsuitable due to its long-term underperformance [9] - Retirees prioritizing income generation may also find better yield opportunities in other sectors without sacrificing stability [9] Alternative Options - Vanguard Health Care ETF (VHT) is presented as an alternative, with a slightly higher expense ratio of 0.09%, larger asset base of $20.4 billion, and a higher dividend yield of 1.38% [11] - VHT's longer track record since 2004 and superior liquidity may provide additional confidence for long-term investors [11] Tactical Allocation - FHLC may serve as a tactical allocation for investors seeking low-cost exposure to the healthcare sector, but concentration risk and historical underperformance necessitate careful position sizing [12]

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

Group 1: Market Performance - The Medical-Biomed/Biotech industry group saw a significant surge in 2025, ending the year with a nearly 34% gain [4] - Eli Lilly (LLY) stock is highlighted as a key pick, having achieved a roughly 37% gain in 2025, outperforming the S&P 500 [5] Group 2: Company Developments - Eli Lilly is noted for being the first in its group to reach a $1 trillion valuation [5] - The company is planning to acquire Ventyx Biosciences for $1.2 billion, which could benefit other companies like Neumora and Neurocrine [11] Group 3: Investment Strategies - Swing trading strategies for Eli Lilly stock include selling into strength, selling into weakness, and cutting losses quickly [8][9]

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures ("Vida†), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co. ...

Core Insights - The upcoming JPMorgan Healthcare Conference is expected to set the tone for the healthcare industry in 2026, with major updates from biotech and pharma executives [3] - The industry landscape has shifted positively with significant drug pricing deals made with President Trump, alleviating concerns over sector-specific tariffs [4] - A looming $300 billion patent cliff by the end of the decade poses a challenge for major pharmaceutical companies, necessitating strategies to offset revenue losses from blockbuster drugs [5] Company-Specific Updates - Bristol Myers Squibb faces the highest exposure to the upcoming loss of exclusivity cycle, but has several data readouts planned for this year that may clarify its growth potential post-2028 [6] - Investors are keen on the ADEPT program trials for Bristol Myers Squibb's Cobenfy, which has a reasonable probability of success according to JPMorgan analysts [7] - Merck's management of Keytruda's loss of exclusivity appears more manageable with the recent approval of a subcutaneous form, which could protect 20% to 30% of U.S. sales [8] - Merck is reportedly in talks to acquire Revolution Medicines, a cancer drugmaker valued over $20 billion, indicating potential growth strategies [9] Market Dynamics - The GLP-1 weight-loss drug market is a focal point, with Novo Nordisk and Eli Lilly preparing to launch new products, while other companies like Amgen and AstraZeneca are also looking to enter the market [9][11] - Novo Nordisk's Wegovy pill has begun reaching patients, and Eli Lilly's orforglipron is expected to receive FDA approval in the first half of the year [10] - The evolving dynamics of the GLP-1 market will be a topic of discussion, particularly regarding direct-to-consumer channels and Medicare coverage for obesity drugs [11]

Group 1: Eli Lilly and Company - Eli Lilly reported a significant increase in revenue, driven by strong sales of its diabetes and cancer drugs, with a year-over-year growth of 15% [1] - The company has expanded its pipeline with new drug candidates, aiming to address unmet medical needs in various therapeutic areas [1] - Eli Lilly's strategic focus on innovation and market expansion is expected to enhance its competitive position in the pharmaceutical industry [1] Group 2: Weatherford International PLC - Weatherford International has shown improvement in operational efficiency, resulting in a 10% reduction in costs compared to the previous year [1] - The company is benefiting from the recovery in oil prices, which has led to increased demand for its services in the oil and gas sector [1] - Weatherford's strategic initiatives include enhancing its technology offerings to better serve its clients and capture market share [1] Group 3: Pagaya - Pagaya has experienced rapid growth in its asset management business, with assets under management increasing by 25% over the last quarter [1] - The company is leveraging advanced data analytics to optimize investment strategies and improve returns for its clients [1] - Pagaya's focus on technology-driven solutions positions it well in the competitive landscape of financial services [1]